PTTG1 attenuates drug-induced cellular senescence

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Tong, Yunguang ^a   Zhao, Weijiang ^a   Zhou, Cuiqi ^a   Wawrowsky, Kolja ^a   Melmed, Shlomo ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; PROTEIN P21; PROTEIN P300; PROTEIN P53; SECURIN; TRANSCRIPTION FACTOR SP1; TRICHOSTATIN A; ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE INHIBITOR 1A; HYDROXAMIC ACID; PITUITARY TUMOR TRANSFORMING PROTEINS; PITUITARY TUMOR-TRANSFORMING PROTEINS; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER THERAPY; CELL AGING; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DAMAGE; DRUG MECHANISM; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LOW DRUG DOSE; MITOSIS; MOUSE; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIDE EFFECT; TRANSCRIPTION REGULATION; TREATMENT OUTCOME; TUMOR XENOGRAFT; ANIMAL; CELL STRAIN HCT116; COLON TUMOR; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; GENE SILENCING; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; MUTATION; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; PROMOTER REGION; RNA INTERFERENCE; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL AGING; CELL LINE, TUMOR; COLONIC NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FEMALE; GENE KNOCKDOWN TECHNIQUES; HCT116 CELLS; HUMANS; HYDROXAMIC ACIDS; IMMUNOHISTOCHEMISTRY; MICE; MICE, NUDE; MUTATION; NEOPLASM PROTEINS; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; RNA INTERFERENCE; SP1 TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80051749424     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0023754     Document Type: Article

References (50)

1. Pei L, Melmed S, (1997) Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Mol Endocrinol 11: 433-441.
2. Vlotides G, Eigler T, Melmed S, (2007) Pituitary tumor-transforming gene: physiology and implications for tumorigenesis. Endocr Rev 28: 165-186.
3. Ogbagabriel S, Fernando M, Waldman FM, Bose S, Heaney AP, (2005) Securin is overexpressed in breast cancer. Mod Pathol 18: 985-990.
4. Thompson AD 3rd, Kakar SS, (2005) Insulin and IGF-1 regulate the expression of the pituitary tumor transforming gene (PTTG) in breast tumor cells. FEBS Lett 579: 3195-3200.
5. Solbach C, Roller M, Fellbaum C, Nicoletti M, Kaufmann M, (2004) PTTG mRNA expression in primary breast cancer: a prognostic marker for lymph node invasion and tumor recurrence. Breast 13: 80-81.
6. Hlubek F, Pfeiffer S, Budczies J, Spaderna S, Jung A, et al. (2006) Securin (hPTTG1) expression is regulated by beta-catenin/TCF in human colorectal carcinoma. Br J Cancer 94: 1672-1677.
7. Heaney AP, Singson R, McCabe CJ, Nelson V, Nakashima M, et al. (2000) Expression of pituitary-tumour transforming gene in colorectal tumours. Lancet 355: 716-719.
8. Sanchez-Puig N, Veprintsev DB, Fersht AR, (2005) Human full-length Securin is a natively unfolded protein. Protein Sci 14: 1410-1418.
9. Tong Y, Tan Y, Zhou C, Melmed S, (2007) Pituitary tumor transforming gene interacts with Sp1 to modulate G1/S cell phase transition. Oncogene 26: 5596-5605.
10. Tong Y, Ben-Shlomo A, Zhou C, Wawrowsky K, Melmed S, (2008) Pituitary tumor transforming gene 1 regulates Aurora kinase A activity. Oncogene 27: 6385-6395.
11. Zou H, McGarry TJ, Bernal T, Kirschner MW, (1999) Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. Science 285: 418-422.
12. Waizenegger I, Gimenez-Abian JF, Wernic D, Peters JM, (2002) Regulation of human separase by securin binding and autocleavage. Curr Biol 12: 1368-1378.
13. Zhang X, Horwitz GA, Prezant TR, Valentini A, Nakashima M, et al. (1999) Structure, expression, and function of human pituitary tumor-transforming gene (PTTG). Mol Endocrinol 13: 156-166.
14. Yu R, Ren SG, Horwitz GA, Wang Z, Melmed S, (2000) Pituitary tumor transforming gene (PTTG) regulates placental JEG-3 cell division and survival: evidence from live cell imaging. Mol Endocrinol 14: 1137-1146.
15. Pei L, (2001) Identification of c-myc as a down-stream target for pituitary tumor-transforming gene. J Biol Chem 276: 8484-8491.
16. Bernal JA, Luna R, Espina A, Lazaro I, Ramos-Morales F, et al. (2002) Human securin interacts with p53 and modulates p53-mediated transcriptional activity and apoptosis. Nat Genet 32: 306-311.
17. Yu R, Heaney AP, Lu W, Chen J, Melmed S, (2000) Pituitary tumor transforming gene causes aneuploidy and p53-dependent and p53-independent apoptosis. J Biol Chem 275: 36502-36505.
18. Donangelo I, Gutman S, Horvath E, Kovacs K, Wawrowsky K, et al. (2006) Pituitary tumor transforming gene overexpression facilitates pituitary tumor development. Endocrinology 147: 4781-4791.
19. Abbud RA, Takumi I, Barker EM, Ren SG, Chen DY, et al. (2005) Early multipotential pituitary focal hyperplasia in the alpha-subunit of glycoprotein hormone-driven pituitary tumor-transforming gene transgenic mice. Mol Endocrinol 19: 1383-1391.
20. Chesnokova V, Kovacs K, Castro AV, Zonis S, Melmed S, (2005) Pituitary hypoplasia in Pttg-/- mice is protective for Rb+/- pituitary tumorigenesis. Mol Endocrinol 19: 2371-2379.
21. Solbach C, Roller M, Eckerdt F, Peters S, Knecht R, (2006) Pituitary tumor-transforming gene expression is a prognostic marker for tumor recurrence in squamous cell carcinoma of the head and neck. BMC Cancer 6: 242.
22. Ghayad SE, Vendrell JA, Bieche I, Spyratos F, Dumontet C, et al. (2009) Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer. J Mol Endocrinol 42: 87-103.
23. Genkai N, Homma J, Sano M, Tanaka R, Yamanaka R, (2006) Increased expression of pituitary tumor-transforming gene (PTTG)-1 is correlated with poor prognosis in glioma patients. Oncol Rep 15: 1569-1574.
24. Fujii T, Nomoto S, Koshikawa K, Yatabe Y, Teshigawara O, et al. (2006) Overexpression of pituitary tumor transforming gene 1 in HCC is associated with angiogenesis and poor prognosis. Hepatology 43: 1267-1275.
25. Saez C, Martinez-Brocca MA, Castilla C, Soto A, Navarro E, et al. (2006) Prognostic significance of human pituitary tumor-transforming gene immunohistochemical expression in differentiated thyroid cancer. J Clin Endocrinol Metab 91: 1404-1409.
26. Shibata Y, Haruki N, Kuwabara Y, Nishiwaki T, Kato J, et al. (2002) Expression of PTTG (pituitary tumor transforming gene) in esophageal cancer. Jpn J Clin Oncol 32: 233-237.
27. Chesnokova V, Zonis S, Rubinek T, Yu R, Ben-Shlomo A, et al. (2007) Senescence mediates pituitary hypoplasia and restrains pituitary tumor growth. Cancer Res 67: 10564-10572.
28. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, et al. (1998) Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282: 1497-1501.
29. Jallepalli PV, Waizenegger IC, Bunz F, Langer S, Speicher MR, et al. (2001) Securin is required for chromosomal stability in human cells. Cell 105: 445-457.
30. Imaizumi M, Kondo T, Taguchi T, Hattori T, Abe O, et al. (1993) A standardized method of using nude mice for the in vivo screening of antitumor drugs for human tumors. Surg Today 23: 412-419.
31. Trail PA, Willner D, Lasch SJ, Henderson AJ, Greenfield RS, et al. (1992) Antigen-specific activity of carcinoma-reactive BR64-doxorubicin conjugates evaluated in vitro and in human tumor xenograft models. Cancer Res 52: 5693-5700.
32. Rebbaa A, Zheng X, Chou PM, Mirkin BL, (2003) Caspase inhibition switches doxorubicin-induced apoptosis to senescence. Oncogene 22: 2805-2811.
33. Mai A, Massa S, Rotili D, Cerbara I, Valente S, et al. (2005) Histone deacetylation in epigenetics: an attractive target for anticancer therapy. Med Res Rev 25: 261-309.
34. Place RF, Noonan EJ, Giardina C, (2005) HDACs and the senescent phenotype of WI-38 cells. BMC Cell Biol 6: 37.
35. Rebbaa A, Zheng X, Chu F, Mirkin BL, (2006) The role of histone acetylation versus DNA damage in drug-induced senescence and apoptosis. Cell Death Differ 13: 1960-1967.
36. Siddiqui H, Solomon DA, Gunawardena RW, Wang Y, Knudsen ES, (2003) Histone deacetylation of RB-responsive promoters: requisite for specific gene repression but dispensable for cell cycle inhibition. Mol Cell Biol 23: 7719-7731.
37. Gartel AL, Tyner AL, (1999) Transcriptional regulation of the p21((WAF1/CIP1)) gene. Exp Cell Res 246: 280-289.
38. Lu S, Jenster G, Epner DE, (2000) Androgen induction of cyclin-dependent kinase inhibitor p21 gene: role of androgen receptor and transcription factor Sp1 complex. Mol Endocrinol 14: 753-760.
39. Xiao H, Hasegawa T, Isobe K, (2000) p300 collaborates with Sp1 and Sp3 in p21(waf1/cip1) promoter activation induced by histone deacetylase inhibitor. J Biol Chem 275: 1371-1376.
40. Billon N, Carlisi D, Datto MB, van Grunsven LA, Watt A, et al. (1999) Cooperation of Sp1 and p300 in the induction of the CDK inhibitor p21WAF1/CIP1 during NGF-mediated neuronal differentiation. Oncogene 18: 2872-2882.
41. Sowa Y, Orita T, Hiranabe-Minamikawa S, Nakano K, Mizuno T, et al. (1999) Histone deacetylase inhibitor activates the p21/WAF1/Cip1 gene promoter through the Sp1 sites. Ann N Y Acad Sci 886: 195-199.
42. Shay JW, Roninson IB, (2004) Hallmarks of senescence in carcinogenesis and cancer therapy. Oncogene 23: 2919-2933.
43. Mooi WJ, Peeper DS, (2006) Oncogene-induced cell senescence-halting on the road to cancer. N Engl J Med 355: 1037-1046.
44. Lehmann BD, McCubrey JA, Jefferson HS, Paine MS, Chappell WH, et al. (2007) A dominant role for p53-dependent cellular senescence in radiosensitization of human prostate cancer cells. Cell Cycle 6: 595-605.
45. Schmitt CA, Fridman JS, Yang M, Lee S, Baranov E, et al. (2002) A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 109: 335-346.
46. Gunven P, Theve NO, Peterson C, (1986) Serum and tissue concentrations of doxorubicin after IV administration of doxorubicin or doxorubicin-DNA complex to patients with gastrointestinal cancer. Cancer Chemother Pharmacol 17: 153-156.
47. Kim DS, Franklyn JA, Smith VE, Stratford AL, Pemberton HN, et al. (2007) Securin induces genetic instability in colorectal cancer by inhibiting double-stranded DNA repair activity. Carcinogenesis 28: 749-759.
48. Bernal JA, Roche M, Mendez-Vidal C, Espina A, Tortolero M, et al. (2008) Proliferative potential after DNA damage and non-homologous end joining are affected by loss of securin. Cell Death Differ 15: 202-212.
49. Chesnokova V, Zonis S, Kovacs K, Ben-Shlomo A, Wawrowsky K, et al. (2008) p21(Cip1) restrains pituitary tumor growth. Proc Natl Acad Sci U S A 105: 17498-17503.
50. Chang BD, Xuan Y, Broude EV, Zhu H, Schott B, et al. (1999) Role of p53 and p21waf1/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs. Oncogene 18: 4808-4818.